SecBot SecBot
PRESS-RELEASE ·Filed Jul 30, 2026

PEN

Penumbra, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss is material, but the pending BSX acquisition at a premium likely provides a floor. Monitor for regulatory updates on the deal close; any delay or termination risk would expose the stock to the full EPS miss. The lack of guidance removes a typical catalyst, making the stock a binary bet on deal completion.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$321.19
T+0 close · Jul 30, 2026 · via day close
Latest settled
+1.25%
T+60 · $325.22
Vs SPY
−1.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 31 $321.19entry
  2. T+1 · 4mo ago +0.57%α −0.85% · $323.02
  3. T+5 · 3mo ago +1.08%α −2.43% · $324.66
  4. T+20 · 3mo ago +0.15%α −2.84% · $321.68
  5. T+60 · 22d ago +1.25%α −1.20% · $325.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Penumbra reported Q2 2026 revenue of $390.0M (+14.9% YoY), in line with consensus, but EPS of $0.88 (diluted) missed the $1.18 consensus estimate by 25.4%. The company is not providing guidance due to the pending acquisition by Boston Scientific (BSX), which introduces deal-closing risk and removes the typical earnings catalyst. The EPS miss is significant, but the acquisition premium likely caps downside.

Key Financial Metrics

EPS
$0.88
est $1.18 · -25.4%
Revenue
$390.0M
est $390.1M · -0.0% · +14.9% YoY
Rating
miss
Gross Margin
67.9%

Key Facts

  • Revenue of $390.0M, +14.9% YoY, in line with $390.1M consensus
  • Diluted EPS of $0.88, missed consensus of $1.18 by 25.4%
  • Net income of $34.8M, down from $45.3M in Q2 2025
  • Global thrombectomy revenue $259.0M (+12.5% YoY); embolization & access $131.1M (+20.0% YoY)
  • Gross margin improved 190bps to 67.9%
  • Operating expenses rose 22.2% YoY, including $6.9M in acquisition-related costs
  • No FY2026 guidance provided due to pending Boston Scientific acquisition
  • Cash & investments of $658.8M as of June 30, 2026

Financial Impact

EPS miss of $0.30 vs consensus; revenue in line; net income down 23% YoY

epsnet incomeoperating expenses

Risk Factors

  • Pending Boston Scientific acquisition may not close on expected timeline or at all
  • EPS miss signals potential operational or margin pressure beyond acquisition costs
  • No guidance removes forward visibility, increasing uncertainty

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
33% bullish (21 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302838410

Track record

11 reports on PEN

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +1.63% at T+20 after the May 6, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $321.46 Now $320.62 −0.26% settles Feb 8
  2. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $319.21 Now $320.62 +0.44% settles Feb 4
  3. Oct 29, 202618d ago 8-K Neutral 5/10 No price data
  4. Oct 29, 202618d ago Press Release Neutral 5/10 Entry $318.95 Now $320.62 +0.52% settles Jan 28
  5. Jul 30, 202615w ago Press Release Bearish 6/10 Viewing Entry $321.19 to $325.22 Now $320.62 +0.18% ▼ −1.25% +1.20% vs SPY
  6. May 7, 202627w ago 425 Bullish 7/10 Entry $324.65 to $323.02 Now $320.62 −1.24% ▼ −0.50% −4.34% vs SPY
  7. May 6, 202627w ago 8-K Bearish 6/10 Entry $324.65 to $323.02 Now $320.62 +1.24% ▲ +0.50% +4.34% vs SPY
  8. Apr 29, 202628w ago DEFA14A Neutral 2/10 Entry $326.48 to $319.49 Now $320.62 −1.79% ▼ −2.14% −5.25% vs SPY
  9. Apr 17, 202630w ago 425 Neutral 4/10 Entry $329.71 to $316.73 Now $320.62 −2.76% ▼ −3.94% −10.71% vs SPY
  10. Apr 1, 202632w ago DEFM14A Bullish 8/10 Entry $330.36 to $315.75 Now $320.62 −2.95% ▼ −4.42% −18.58% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Wed (10h 23m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026